Walvax Biotechnology Co., Ltd. (SHE:300142)
China
· Delayed Price · Currency is CNY 11.71
+0.04 (0.34%)
At close: Dec 5, 2025
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
| Autonomous Vaccine | 4.08B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Intermediate Products | 17.22M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Intermediate Products Growth | -36.61% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Technical Services | 11.02M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Technical Services Growth | -33.40% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Business | 7.92M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Business Growth | 3.51% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Non-immunization Program Vaccines | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Immunization Program Vaccines | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| 13-valent Pneumococcal Polysaccharide Conjugate Vaccine | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| 23-valent Pneumococcal Polysaccharide Vaccine | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Haemophilus Influenza Type B | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Freeze-dried AC Vaccine Group Meningococcal Polysaccharide Conjugate Vaccine | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Group A and C Meningococcal Polysaccharide Vaccine | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| ACYW135 Meningococcal Polysaccharide Vaccine | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Absorbed Acellular Diphtheria Combined Vaccine | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Production | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Production Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Research and Development | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Research and Development Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inter-segment Eliminations | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inter-segment Eliminations Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inter-segment Eliminations | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inter-segment Eliminations Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Revenue by Geography
Fiscal year is January - December.
Fiscal Year | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2016 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2016 - 2018 |
| Inter-segment Eliminations | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inter-segment Eliminations Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China | 3.83B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| China Growth | -20.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas | 287.54M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Overseas Growth | 1.46% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inter-segment Eliminations | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Inter-segment Eliminations Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|